kanser hastalarında hiperbilirubinemi
Küçük Resim Yok
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Trakya Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Kanser, vücudun her organında veya dokusunda anormal hücrelerin kontrolsüz bir şekilde büyüyüp normal sınırlarını aşarak vücudun farklı bölgelerini işgal edebilen ve/veya diğer organlara yayılmasıyla ortaya çıkabilen geniş bir hastalık grubudur. Hiperbilirubinemi kanser hastalarında rastlanabilen klinik durumlardan biridir. Malignite ilişkili hiperbilirubinemi yaygın karaciğer metastazına, posthepatik mekanik nedenlere, ilaç toksisitesine ve metabolik nedenlere bağlı olarak gelişebilmektedir. Perkütan Transhepatik Kolanjiografi (PTK) ve Endoskopik Retrograd Kolanjiopankreotografi (Endoscopic Retrograde Cholangiopancreatography-ERCP) gibi biliyer drenaj yöntemleri sarılıkla ilişkili komplikasyonları azaltmak ve antitümör tedaviye olanak sağlamak amacıyla kullanılabilmektedir. Çalışmamızın amacı kanser tanısı olan ve hiperbilirubinemi izlenen hastaların girişimsel işlemler öncesi ve sonrası durumunun kıyaslanması, sağkalımlarının incelenmesiydi. Bu nedenle, hiperbilirubinemi izlenen kanser olgularının demografik ve klinik özellikleri, laboratuvar değerleri, yapılan terapötik işlemler, kemoterapi tedavilerine devamlılıkları, yaşam analizleri değerlendirildi. Çalışmamızda 2015 ile 2022 yılları arasında Trakya Üniversitesi Tıp Fakültesi Tıbbi Onkoloji polikliniğinde ve servisinde takip edilmiş ve hastalığın herhangi bir evresinde total bilirubin düzeyi 5 mg/dl ve üzeri olan kanser tanılı 103 hastanın verileri retrospektif olarak değerlendirildi. Yapılan istatistiksel analizler sonucunda işlem yapılan ve başarılı bir şekilde bilirubin düşüşü sağlanan hasta popülasyonlarında hem sağkalımın uzadığı hem de kemoterapi alabilirliklerinin arttığı gözlemlendi. Ayrıca tanı sırasında hiperbilirubinemi tanısı alan grupta sağkalım istatistiksel olarak anlamlı düzeyde daha uzun bulundu. Anahtar Kelimeler: Kanser, hiperbilirubinemi, Perkütan Transhepatik Kolanjiografi, Endoskopik Retrograd Kolanjiopankreotografi
Cancer is a large group of diseases that can occur when abnormal cells grow uncontrollably in every organ or tissue of the body, exceed their normal limits, invade different parts of the body and/or spread to other organs. Hyperbilirubinemia is one of the clinical conditions that can be encountered in cancer patients. Malignant hyperbilirubinemia may develop due to extensive liver metastasis, posthepatic mechanical causes, drug toxicity and metabolic causes. Biliary drainage methods such as Percutaneous Transhepatic Cholangiography (PTC) and Endoscopic Retrograde Cholangiopancreatography (ERCP) can be used to reduce the complications associated with jaundice and to enable antitumor therapy. The aim of our study was to compare the condition of patients with cancer and hyperbilirubinemia before and after interventional procedures, and to examine their survival. For this reason, demographic and clinical characteristics, laboratory values, therapeutic procedures, continuity of chemotherapy treatments, and survival analyzes of cancer cases with hyperbilirubinemia were evaluated. In our study, the data of 103 patients diagnosed with cancer with a total bilirubin level of 5 mg/dl and above at any stage of the disease, who were followed up in the Medical Oncology outpatient clinic and service of Trakya University Faculty of Medicine between 2015 and 2022, were evaluated retrospectively. As a result of the statistical analyzes performed, it was observed that both the survival time and the ability to receive chemotherapy increased in the patient populations who were treated and successfully decreased bilirubin. In addition, survival was statistically significantly longer in the group diagnosed with hyperbilirubinemia at the time of diagnosis. Key Words: Cancer, hyperbilirubinemia, Percutaneous Transhepatic Cholangiography, Endoscopic Retrograde Cholangiopancreatography
Cancer is a large group of diseases that can occur when abnormal cells grow uncontrollably in every organ or tissue of the body, exceed their normal limits, invade different parts of the body and/or spread to other organs. Hyperbilirubinemia is one of the clinical conditions that can be encountered in cancer patients. Malignant hyperbilirubinemia may develop due to extensive liver metastasis, posthepatic mechanical causes, drug toxicity and metabolic causes. Biliary drainage methods such as Percutaneous Transhepatic Cholangiography (PTC) and Endoscopic Retrograde Cholangiopancreatography (ERCP) can be used to reduce the complications associated with jaundice and to enable antitumor therapy. The aim of our study was to compare the condition of patients with cancer and hyperbilirubinemia before and after interventional procedures, and to examine their survival. For this reason, demographic and clinical characteristics, laboratory values, therapeutic procedures, continuity of chemotherapy treatments, and survival analyzes of cancer cases with hyperbilirubinemia were evaluated. In our study, the data of 103 patients diagnosed with cancer with a total bilirubin level of 5 mg/dl and above at any stage of the disease, who were followed up in the Medical Oncology outpatient clinic and service of Trakya University Faculty of Medicine between 2015 and 2022, were evaluated retrospectively. As a result of the statistical analyzes performed, it was observed that both the survival time and the ability to receive chemotherapy increased in the patient populations who were treated and successfully decreased bilirubin. In addition, survival was statistically significantly longer in the group diagnosed with hyperbilirubinemia at the time of diagnosis. Key Words: Cancer, hyperbilirubinemia, Percutaneous Transhepatic Cholangiography, Endoscopic Retrograde Cholangiopancreatography
Açıklama
Tıpta Uzmanlık
Anahtar Kelimeler
İç Hastalıkları, Internal diseases
